Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell.

Abstract:

:Haplo-identical transplant is being increasingly used in patients who do not have a readily available matched related or unrelated donor. Post-transplant cyclophosphamide's use due to its simplicity and documented efficacy has made this approach readily employable across diverse transplant centres across the globe. The outcomes of regimens used for conditioning in recipients of bone marrow are at times in variance to that from more commonly employed G-CSF mobilised peripheral stem cell (PBSC). This review highlights various conditioning regimens used in PBSC recipients, with emphasis on toxicities, practicalities and transplant related outcomes of relapse, non-relapse mortality and graft versus host disease.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Patil S,Potter V,Mohty M

doi

10.1016/j.ctrv.2020.102071

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

102071

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(20)30109-2

journal_volume

89

pub_type

杂志文章,评审
  • The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.

    abstract::Dysregulated activation of the MET tyrosine kinase receptor is implicated in the development of solid tumors and can arise through several mechanisms, including gene amplification, overexpression of the receptor and/or its ligand hepatocyte growth factor (HGF), and the acquisition of activating mutations. The most com...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102022

    authors: Salgia R,Sattler M,Scheele J,Stroh C,Felip E

    更新日期:2020-07-01 00:00:00

  • Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

    abstract::Hepatocellular carcinoma (HCC) is one of the most frequent and deadliest cancers worldwide. Liver transplantation, surgical resection or local ablation offer the best survival advantages but most patients either present when the tumor is in an advanced stage or the degree of underlying liver disease precludes these op...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.05.002

    authors: Meza-Junco J,Montano-Loza AJ,Liu DM,Sawyer MB,Bain VG,Ma M,Owen R

    更新日期:2012-02-01 00:00:00

  • Novel therapeutic approaches to the treatment of metastatic breast cancer.

    abstract::Metastatic breast cancer is ultimately an incurable disease, although recent data have shown that its incidence is decreasing and that patients with metastatic breast cancer live longer. This improvement in survival seems to be linked with the introduction of new therapeutic agents, novel combinations of existing ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.10.001

    authors: Fernández Y,Cueva J,Palomo AG,Ramos M,de Juan A,Calvo L,García-Mata J,García-Teijido P,Peláez I,García-Estévez L

    更新日期:2010-02-01 00:00:00

  • Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

    abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.007

    authors: Chargari C,Kirov KM,Bollet MA,Magné N,Védrine L,Cremades S,Beuzeboc P,Fourquet A,Kirova YM

    更新日期:2011-06-01 00:00:00

  • Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

    abstract::Bruton's tyrosine kinase (BTK) is a non-receptor intracellular kinase that belongs to the TEC-family tyrosine kinases together with bone marrow-expressed kinase (BMX), redundant-resting lymphocyte kinase (RLK), and IL-2 inducible T-Cell kinase (ITK). All these proteins play a key role in the intracellular signaling of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.06.001

    authors: Molina-Cerrillo J,Alonso-Gordoa T,Gajate P,Grande E

    更新日期:2017-07-01 00:00:00

  • Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

    abstract::Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.05.003

    authors: von Moos R,Costa L,Gonzalez-Suarez E,Terpos E,Niepel D,Body JJ

    更新日期:2019-06-01 00:00:00

  • Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

    abstract::The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.05.005

    authors: Kunc M,Biernat W,Senkus-Konefka E

    更新日期:2018-06-01 00:00:00

  • Fertility issues in survivors from adolescent cancers.

    abstract::Infertility is a common and distressing late-effect of cancer treatment. Whist sperm banking for post-pubertal males and embryo freezing for women (who are in a stable relationship at the time of treatment) are highly successful fertility preservation strategies, for females without a partner (including young and pre-...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.02.001

    authors: Pacey AA

    更新日期:2007-11-01 00:00:00

  • Cancer stem cells niche: a target for novel cancer therapeutics.

    abstract::Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.004

    authors: Yi SY,Hao YB,Nan KJ,Fan TL

    更新日期:2013-05-01 00:00:00

  • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

    abstract::Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.012

    authors: McDermott D,Lebbé C,Hodi FS,Maio M,Weber JS,Wolchok JD,Thompson JA,Balch CM

    更新日期:2014-10-01 00:00:00

  • SARS-CoV-2 and cancer: Are they really partners in crime?

    abstract::The outbreak of the SARS-CoV-2 pandemic has overwhelmed health care systems in many countries. The clinical presentation of the SARS-CoV-2 varies between a subclinical or flu-like syndrome to that of severe pneumonia with multi-organ failure and death. Initial reports have suggested that cancer patients may have a hig...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102068

    authors: van Dam PA,Huizing M,Mestach G,Dierckxsens S,Tjalma W,Trinh XB,Papadimitriou K,Altintas S,Vermorken J,Vulsteke C,Janssens A,Berneman Z,Prenen H,Meuris L,Vanden Berghe W,Smits E,Peeters M

    更新日期:2020-09-01 00:00:00

  • Fertility preservation in cancer patients: the global framework.

    abstract::Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 80% of survivors affected. None of the established or experimental fertility preservation methods can assure parenthood, rather they may provide a future opportunity to overcome treatment induced sterility. Around 70-75% of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.001

    authors: Linkeviciute A,Boniolo G,Chiavari L,Peccatori FA

    更新日期:2014-09-01 00:00:00

  • Branchiogenic carcinoma--conceptual or true clinico-pathological entity?

    abstract::The existence of branchiogenic carcinoma remains controversial. According to some authors, this malignancy is more conceptual than a true clinicopathologic entity. The originally proposed diagnostic criteria of branchiogenic carcinoma have been subsequently challenged. Many reports regarding primary branchiogenic carc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2004.12.007

    authors: Jereczek-Fossa BA,Casadio C,Jassem J,Luzzatto F,Viale G,Bruschini R,Chiesa F,Orecchia R

    更新日期:2005-04-01 00:00:00

  • Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

    abstract:BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.07.011

    authors: Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

    更新日期:2018-11-01 00:00:00

  • Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures.

    abstract::Radiotherapy is an indispensable unit of multidisciplinary treatment of breast cancer. Although the application of modern techniques has led to a significantly reduction in radiation-induced heart disease, it is still recognized as the leading causes of morbidity and mortality among breast cancer survivors. With the g...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.03.008

    authors: Zhu Q,Kirova YM,Cao L,Arsene-Henry A,Chen J

    更新日期:2018-07-01 00:00:00

  • Early diagnosis and surgical management of prostate cancer.

    abstract::Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00096-3

    authors: Linton KD,Hamdy FC

    更新日期:2003-06-01 00:00:00

  • Opioid switching: a systematic and critical review.

    abstract::Cancer patients with pain may not respond to increasing doses of opioids because they develop adverse effects before achieving an acceptable analgesia, or the analgesic response is poor, despite a rapid dose escalation. Opioid switching may significantly improve the balance between analgesia and adverse effects. We co...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2006.03.001

    authors: Mercadante S,Bruera E

    更新日期:2006-06-01 00:00:00

  • Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.

    abstract::In the last ten years, the development of several novel targeted drugs and the refinement of state of the art technologies such as the genomics and proteomics and their introduction to clinical practice have revolutionized the management of patients affected by cancer. However, everyday practice points out several cli...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.10.001

    authors: Pantaleo MA,Nannini M,Maleddu A,Fanti S,Ambrosini V,Nanni C,Boschi S,Biasco G

    更新日期:2008-04-01 00:00:00

  • Langerhans cell histiocytosis: Current concepts and treatments.

    abstract::Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of cells with the phenotype of activated Langerhans cells. The diagnosis of LCH is often delayed or missed. Many questions about LCH remain to be answered, including whether it is caused by a malignancy or by immune dysregulation. Data from the early...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.012

    authors: Abla O,Egeler RM,Weitzman S

    更新日期:2010-06-01 00:00:00

  • Preoperative chemotherapy for non-small cell lung cancer.

    abstract::Surgery has been considered the standard of care in patients with early-stage non-small cell lung cancer (NSCLC), as well as in some cases of stage III, for a long time. Poor survival after complete resection has led to the search for new therapeutic strategies such as combining anticancer treatments. However, at the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0218

    authors: Depierre A,Westeel V,Jacoulet P

    更新日期:2001-04-01 00:00:00

  • CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

    abstract::Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other pa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.11.007

    authors: Tokunaga R,Zhang W,Naseem M,Puccini A,Berger MD,Soni S,McSkane M,Baba H,Lenz HJ

    更新日期:2018-02-01 00:00:00

  • Exercise and cancer rehabilitation: a systematic review.

    abstract:INTRODUCTION:Cancer is increasingly being viewed as a chronic illness requiring long-term management, and there is a growing need for evidence-based rehabilitation interventions for cancer survivors. Previous reviews have evaluated the benefits of exercise interventions for patients undergoing cancer treatment and long...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.11.003

    authors: Spence RR,Heesch KC,Brown WJ

    更新日期:2010-04-01 00:00:00

  • Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.

    abstract::Solid tumours contain regions of hypoxia, which may be a prognostic indicator and determinant of malignant progression, metastatic development and chemoradio-resistance. The degree of intra-tumoural hypoxia has been shown to be positively correlated with the expression of the transcription factor hypoxia-inducible fac...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.05.003

    authors: O'Donnell JL,Joyce MR,Shannon AM,Harmey J,Geraghty J,Bouchier-Hayes D

    更新日期:2006-10-01 00:00:00

  • Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.

    abstract::Management of early stages non-small cell lung carcinoma has traditionally been surgery with radiation selected for medically inoperable patients. Recent emergence of stereotactic body radiation therapy allows for delivery of high radiation dose to the tumor while sparing normal lungs. This reviews compares loco-regio...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.06.001

    authors: Nguyen NP,Garland L,Welsh J,Hamilton R,Cohen D,Vinh-Hung V

    更新日期:2008-12-01 00:00:00

  • Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.

    abstract:BACKGROUND:Surgery is the only curative treatment for primary cutaneous melanoma, therefore it is important to determine excision margins that minimise risk of local recurrence, distant recurrence and death. METHODS:MEDLINE, EMBASE and Cochrane CENTRAL were searched from 2009 to 2015. Inclusion criteria were: populati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2015.10.013

    authors: Wheatley K,Wilson JS,Gaunt P,Marsden JR

    更新日期:2016-01-01 00:00:00

  • Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

    abstract::Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90028-5

    authors: Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

    更新日期:1989-06-01 00:00:00

  • Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).

    abstract::The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC) remains poor. For first-line therapy, a number of platinum-based regimens are standard; second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. Treatment options for patients whose tumors have failed to res...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.05.003

    authors: Langer CJ,Mok T,Postmus PE

    更新日期:2013-05-01 00:00:00

  • Cancer surgery: the last 25 years.

    abstract::Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 历史文章,杂志文章,评审

    doi:10.1053/ctrv.1999.0147

    authors: Bremers AJ,Rutgers EJ,van de Velde CJ

    更新日期:1999-12-01 00:00:00

  • RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

    abstract::Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene express...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.08.004

    authors: Barata P,Sood AK,Hong DS

    更新日期:2016-11-01 00:00:00

  • The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.

    abstract::With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00038-5

    authors: Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

    更新日期:2002-08-01 00:00:00